Alvotech and Advanz Pharma extend their partnership to commercialize 5 biosimilar candidates across Europe.
Iceland-based Alvotech announced that it will extend its partnership with Advanz Pharma to commercialize 5 new biosimilars across Europe. Under the agreement, Alvotech will be responsible for development and commercial supply and Advanz Pharma will be in charge of registration and commercialization in Europe.
The deal includes a biosimilars for Simponi (golimumab) and Entyvio (vedolizumab) as well as 3 early-stage undisclosed biosimilar candidates. Simponi is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Entyvio is indicated for ulcerative colitis and Crohn disease. According to IQVIA, the current addressable market for the 5 biosimilar candidates is worth upwards of $4 billion.
“We are very excited to extend our existing partnership with Advanz Pharma into additional therapeutic areas. The growth of our collaboration is based on a common vision and commitment to provide better patient access to more affordable biologics,” said Robert Wessman, chairman and CEO of Alvotech.
In February 2023 Alvotech and Advanz Pharma announced that the companies had entered into an exclusive agreement for the commercialization of AVT23, a proposed biosimilar to Xolair (omalizumab). The agreement covers the European Economic Area, the United Kingdom, Switzerland, Canada, Australia, and New Zealand.
“After signing our initial partnership agreement with Advanz earlier this year, we look forward to deepening our relationship and working with Advanz on bringing additional important therapies to market in Europe,” commented Anil Okay, chief commercial officer of Alvotech.
A confirmatory patient study for the golimumab biosimilar (AVT05) is underway, and marked the fifth internally developed portfolio candidate to be dosed in a patient study.
Alvotech Earnings Report
The news comes after Alvotech published its earnings for the first quarter of 2023. During the first 3 months of the year, the company’s revenue increased to $15.9 million, about $15 million more than the same period in 2022 ($0.8 million).
As of March 31, 2023, Alvotech claimed that it had cash and cash equivalents of $115.8 million, excluding $25.2 million of restricted cash. In addition, the company had borrowings of $793.7 million, including $23.0 million of current portion of borrowings.
Cost of product revenue was $39.1 million, which Alvotech said was primarily a result of product revenues for AVT02, the company’s adalimumab biosimilar, in certain European countries and Canada.
Alvotech is also working to address issues with its manufacturing facility that were outlined in an FDA complete response letter for the company’s biologics license application for AVT02. The company is anticipating the FDA to give its final approval decision in late June 2023, in time for a US launch in July 2023.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.